Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma

American Journal of Gastroenterology

Volumn 109, Issue 1, 2014, Pages 36-45

  Xu, Yi Wei ^a,b   Peng, Yu Hui ^b   Chen, Bo ^a   Wu, Zhi Yong ^a,c   Wu, Jian Yi ^a   Shen, Jin Hui ^c   Zheng, Chun Peng ^c   Wang, Shao Hong ^c   Guo, Hai Peng ^b   Li, En Min ^a   Xu, Li Yan ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c SHANTOU CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; BMI1 PROTEIN; HEAT SHOCK PROTEIN 70; MATRILYSIN; NY ESO 1 ANTIGEN; PEROXIREDOXIN 6; PROTEIN P53; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; EARLY CANCER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMOKING; THORAX CANCER; TUMOR INVASION; BLOOD; CLASSIFICATION; COHORT ANALYSIS; ESOPHAGUS TUMOR; IMMUNOLOGY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS;

EID: 84891922151     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.384     Document Type: Article

References (42)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
2. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
3. American Cancer Society. Global Cancer Facts and Figures, 2nd Edition. American Cancer Society Inc.:Atlanta, 2011
4. Takikita M, Hu N, Shou JZ et al. Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma. BMC Cancer 2009;9:310
5. Shimada H, Nabeya Y, Okazumi S et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003;133:486-94
6. Mealy K, Feely J, Reid I et al. Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol 1996;22:505-7
7. Shimada H, Nabeya Y, Okazumi S et al. Prognostic signifi cance of CYFRA 21-1 in patients wiThesophageal squamous cell carcinoma. J Am Coll Surg 2003;196:573-8
8. Kosugi S, Nishimaki T, Kanda T et al. Clinical signifi cance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 2004;28:680-5
9. Frenkel K, Karkoszka J, Glassman T et al. Serum autoantibodies recognizing 5-hydroxymethyl-2 '-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev 1998;7:49-57
10. Zhong L, Coe SP, Stromberg AJ et al. Profi ling tumor-Associated antibodies for early detection of non-small cell lung cancer. J Th orac Oncol 2006;1:513-9
11. Li Y, Karjalainen A, Koskinen H et al. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 2005;114:157-60
12. Trivers GE, De Benedetti VM, Cawley HL et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996;2:1767-75
13. Tan HT, Low J, Lim SG et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009;276:6880-904
14. Zhang JY, Casiano CA, Peng XX et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-Associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43
15. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35
16. Chapman C, Murray A, Chakrabarti J et al. Autoantibodies in breast cancer: Their use as an aid to early diagnosis. Ann Oncol 2007;18:868-73
17. Chapman CJ, Murray A, McElveen JE et al. Autoantibodies in lung cancer: Possibilities for early detection and subsequent cure. Th orax 2008;63:228-33
18. Desmetz C, Bascoul-Mollevi C, Rochaix P et al. Identifi cation of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009;15:4733-41
19. Boyle P, Chapman CJ, Holdenrieder S et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011;22:383-9
20. Chapman CJ, Th orpe AJ, Murray A et al. Immunobiomarkers in small cell lung cancer: Potential early cancer signals. Clin Cancer Res 2011;17:1474-80
21. Massoner P, Lueking A, Goehler H et al. Serum-Autoantibodies for discovery of prostate cancer specifi c biomarkers. Prostate 2012;72:427-36
22. Fujita Y, Nakanishi T, Hiramatsu M et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006;12:6415-20
23. Fujita Y, Nakanishi T, Miyamoto Y et al. Proteomics-based identifi cation of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008;263:280-90
24. Cai HY, Wang XH, Tian Y et al. Changes of serum p53 antibodies and clinical signifi cance of radiotherapy for esophageal squamous cell carcinoma. World J Gastroenterol 2008;14:4082-6
25. Liu WL, Guo XZ, Zhang LJ et al. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer 2010;10:467
26. Zhou JH, Zhang B, Kernstine KH et al. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol 2011;17:1373-8
27. Fujita S, Wada H, Jungbluth AA et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004;10:6551-8
28. Crawford LV, Pim DC, Bulbrook RD. The detection of antibodies against the cellular protein p53 in sera from patients with breast-cancer. Int J Cancer 1982;30:403-8
29. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000;60:1777-88
30. Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: Review of an immunogenic tumor antigen. Adv Cancer Res 2006;95:1-30
31. Crawford HC, Scoggins CR, Washington MK et al. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinarto-ductal metaplasia in exocrine pancreas. J Clin Invest 2002;109:1437-44
32. Rice TW, Blackstone EH, Rusch VW. 7Thedition of the AJCC Cancer Staging Manual: Esophagus and esophagogastric junction. Ann Surg Oncol 2010;17:1721-4
33. Chinese experts in non-surgical clinical staging for esophageal carcinoma. Standard of non-surgical clinical staging for esophageal carcinoma (draft) .Chin J Radiat Oncol 2010;19:179-180
34. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research, 4Thedn, Blackwell Science: Oxford, 2002
35. Nesterova M, Johnson N, Cheadle C et al. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006;1762:398-403
36. Wagner PD, Verma M, Srivastava S. Challenges for biomarkers in cancer detection. Ann NY Acad Sci 2004;1022:9-16
37. Fern á ndez Madrid F. Autoantibodies in breast cancer sera: Candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005;230:187-98
38. Sahin U, T ü reci O, Schmitt H et al. Human neoplasms elicit multiple specifi c immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3
39. Mintz PJ, Kim J, Do KA et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63
40. Klade CS, Voss T, Krystek E, et al. Identifi cation of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001;1:890-8
41. Cheng Y, Xu J, Guo J et al. Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma. Clin Transl Oncol 2013;15:398-402
42. Liu WL, Zhang G, Wang JY et al. Proteomics-based identifi cation of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2008;375:440-5